Orakl Oncology Raises €30 Million Series A

The French TechBio company, spun out of the Gustave Roussy Institute, will use the round to build predictive cancer models.

Updated on Nov. 12, 2026 in Cancer

Orakl Oncology Raises €30 Million Series A

Live Poll

Do you trust that AI will make new cancer drugs safer and more effective?

Orakl Oncology, a French TechBio company, raised €30 million ($34 million) in a Series A round co-led by Norrsken VC and Singular. The round brings the company's total funding to €45 million ($50 million).

Why it matters

Around 75% of oncology candidates fail in Phase 2, largely because the complexity of patient and tumor biology remains poorly understood. Orakl's approach aims to address that gap by modeling cancer biology before clinical trials begin.

Orakl reports its predictive engine has shown 90% accuracy in predicting cancer clinical trial outcomes, against an industry backdrop where roughly 75% of oncology candidates fail in Phase 2. The independent validation of the accuracy claim has not been described in the available information.

The players

Orakl Oncology

A French TechBio company spun out of the Gustave Roussy Institute in 2023, building virtual cancer patient cohorts to predict trial outcomes.

Norrsken VC

A venture capital firm that co-led the Series A round in Orakl Oncology.

Singular

An investor that co-led the Series A round and also led Orakl's earlier Seed round.

The details

Orakl builds cohorts of virtual cancer patients from real patients' tumors grown in the lab, paired with medical history and biological data. Candidate targets are validated on its proprietary patient-derived models through a lab-in-the-loop approach, and more than 15 cancer centres across Europe, North America and Asia are in contract negotiations.

Timeline

  1. December 2024: Orakl closed its €11 million Seed round led by Singular.

  2. November 12, 2026: Orakl announced the €30 million Series A.

Big Picture

Orakl's model targets the Phase 2 bottleneck where roughly 75% of oncology candidates fail, largely because tumor biology remains poorly understood. The round signals investor interest in computational and patient-derived approaches to that specific attrition problem.

For patients, the practical effect of this funding is not immediate, since the company is still building its models and negotiating with cancer centres. Any resulting therapies would need to move through clinical trials before reaching patients.

The takeaway

Investment in predictive modeling reflects a push to reduce the costly late-stage failures that define cancer drug development. Readers tracking cancer research should watch whether such models hold up in independent clinical validation.

Further reading

Explore more on Cancer research and treatment developments.

Live Poll

Do you trust that AI will make new cancer drugs safer and more effective?